natgillin/translations-raw huggingface dataset:
In the second study, involving 269 patients who had not been treated before, Imbruvica was more effective than the cancer medicine chlorambucil at delaying progression of the cancer.
V drugi študiji z 269 bolniki, ki niso bili predhodno zdravljeni, se je pri upočasnitvi napredovanja raka zdravilo Imbruvica izkazalo za učinkovitejše od zdravila za zdravljenje raka, klorambucila.
In the second study, it took 26.4 months for the disease to get worse in patients taking Revlimid plus dexamethasone, compared with 22.7 months for those on standard treatment.
V drugi študiji je trajalo 26,4 meseca, da se je bolezen poslabšala pri bolnikih, ki so jemali Revlimid v kombinaciji z deksametazonom, v primerjavi z 22,7 meseca pri tistih, ki so prejemali standardno zdravljenje.
In the second study, it was the number of patients who had a platelet count between 50,000 and 400,000 per microlitre during six months of treatment.
V drugi študiji je bilo glavno merilo učinkovitosti število bolnikov, pri katerih se je število trombocitov v šestih mesecih zdravljenja gibalo med 50 000 in 400 000 celic na mikroliter.
In the second study, Kiovig was shown to be effective in increasing the platelet count.
V drugi študiji se je zdravilo Kiovig izkazalo kot učinkovito pri povečevanju števila trombocitov.
In the second study, Myocet alone was compared with standard doxorubicin alone in 224 women.
V drugi študiji so pri 224 ženskah zdravilo Myocet kot samostojno zdravilo primerjali s standardnim doksorubicinom kot samostojnim zdravilom.
In the second study, on day 1 the percentage or patients who had reduction of facial redness 3 hours after application was 19.6% (29 out of 148 patients) for Mirvaso compared with 0 % (none out of 145 patients) for placebo.
V drugi študiji je na 1. dan odstotek bolnikov, pri katerih se je rdečina obraza zmanjšala 3 ure po nanosu, znašal 19,6 % (29 od 148 bolnikov) za zdravilo Mirvaso in 0 % (nobeden od 145 bolnikov) za placebo.
In the second study, patients given Yervoy with dacarbazine survived an average of 11 months, compared with 9 months in those given placebo plus dacarbazine, but about a third of the patients given Yervoy were unable to complete treatment due to side effects.
V drugi študiji so bolniki, ki so prejemali zdravilo Yervoy v kombinaciji z dakarbazinom, v povprečju preživeli 11 mesecev v primerjavi z 9 meseci pri bolnikih, ki so prejemali placebo v kombinaciji z dakarbazinom, vendar pa okoli tretjina bolnikov, ki so prejemali zdravilo Yervoy, zaradi neželenih učinkov ni mogla zaključiti zdravljenja.
In the second study, patients receiving Lucentis on its own or as an add-on to laser photocoagulation could see after one year an average of 5 letters more than patients receiving laser photocoagulation on its own.
V drugi študiji so bolniki, ki so prejemali zdravilo Lucentis kot samostojno zdravilo ali dopolnilno zdravljenje k laserski fotokoagulaciji, po enem letu lahko v povprečju videli pet črk več kot bolniki, ki so se zdravili s samostojno lasersko fotokoagulacijo.
In the second study, patients treated with Zytiga lived for an average of around 16 months without their disease getting worse, compared with around 8 months in patients taking placebo.
V drugi študiji so bolniki, ki so prejemali zdravilo Zytiga, v povprečju živeli okoli 16 mesecev brez poslabšanja bolezni, medtem ko je bilo pri bolniki, ki so prejemali placebo, to obdobje trajalo okoli 8 mesecev.
In the second study, progression-free survival was 9.4 months in the patients receiving Avastin and 8.0 months in those receiving placebo.
V drugi študiji je čas preživetja brez napredovanja bolezni znašal 9,4 meseca pri bolnikih, ki so prejemali zdravilo Avastin, in 8,0 meseca pri tistih, ki so prejemali placebo.
In the second study, the brain tumour shrank by at least half in 35% of patients (27 out of 78 patients) treated with Votubia, compared with none of the 39 patients who received placebo.
V drugi študiji se je možganski tumor zmanjšal vsaj za polovico pri 35 % bolnikov (pri 27 bolnikih od 78), zdravljenih z zdravilom Votubia, medtem ko med 39 bolniki, ki so prejemali placebo, do tega ni prišlo pri nobenem bolniku.
In the second study, the estimated risk of having a second attack of demyelination was lower in the patients taking Avonex than in the patients taking placebo: with Avonex, the risk was 21% in two years and 35% in three years, whereas the risk with placebo was 39% in two years and 50% in three years.
V drugi študiji so ocenili, da je tveganje za pojav drugega demielinizacijskega napada manjše pri bolnikih, ki so se zdravili z zdravilom Avonex, kot pri bolnikih, zdravljenih s placebom: pri bolnikih, zdravljenih z zdravilom Avonex, je bilo tveganje 21 % v dveh letih in 35 % v treh, medtem ko je bilo pri bolnikih, ki so prejemali placebo, 39 % v dveh letih in 50 % v treh.
In the second study, the fall in symptom score was 20.0 in the Invega group and 10.8 in the placebo group.
V drugi študiji se je rezultat vrednotenja simptomov pri skupini, ki je jemala zdravilo Invega, znižal za 20,0 točke, pri skupini, ki je jemala placebo, pa za 10,8 točke.
In the second study, the figures were around 22% for Ozurdex after 90 days and 12% for the sham treatment.
V drugi študiji so po 90 dneh dosegli približno 22-odstotno izboljšanje z zdravilom Ozurdex in 12-odstotno izboljšanje z navideznim zdravljenjem.
In the second study, the figures were: 63% (124 out of 198) for patients treated with Yellox and 40% (39 out of 98) for those treated with placebo.
V drugi študiji pa je bil ta delež: 63 % (124 od 198) pri bolnikih, zdravljenimi z zdravilom Yellox, in 40 % (39 od 98) pri bolnikih, ki so jemali placebo.
In the second study, the mean proportion of daily ON time increased by 4.5% (CI95% 0.93%, 7.97%) from baseline.
»ON« povečalo za 4,5 % (CI95% 0,93 %, 7,97 %) glede na izhodiščne vrednosti.
In the second study, the treatment difference in EET between ANORO 55/22 micrograms and placebo was 21.9 seconds (p=0.234) at Week 12.
V drugi študiji je bila razlika EET med zdravilom ANORO 55/22 mikrogramov in placebom 21,9 sekunde (p = 0,234) v 12. tednu.
In the second study, the treatment difference in EET between LAVENTAIR 55/22 micrograms and placebo was 21.9 seconds (p=0.234) at Week 12.
V drugi študiji je bila razlika EET med zdravilom LAVENTAIR 55/22 mikrogramov in placebom 21,9 sekunde (p = 0,234) v 12. tednu.
In the second study, the women whose cancer was expressing large quantities of HER2 taking Tyverb in combination with letrozole survived for an average of 35.4 weeks without their disease getting worse.
V drugi študiji so ženske, katerih rak je izražal velike količine HER2, in ki so zdravilo Tyverb jemale v kombinaciji z letrozolom, v povprečju preživele 35,4 tedna, ne da bi se njihova bolezen poslabšala.
In the second study, the ‘on’ time was increased by 35 minutes compared with placebo.
V drugi študiji je bil v primerjavi s placebom ta čas daljši za 35 minut.
In the second study, three-month treatment with Esmya was as effective as leuprorelin in reducing heavy uterine bleeding, as 90.3% of women treated with Esmya had reduced bleeding compared with 89.1% of women treated with leuprorelin.
V drugi študiji je bilo pri trimesečnem zdravljenju močne krvavitve iz maternice zdravilo Esmya enako učinkovito kot levprorelin, saj se je krvavitev zmanjšala pri 90,3 % žensk, ki so se zdravile z zdravilom Esmya, v primerjavi z 89,1 % tistih, ki so se zdravile z levprorelinom.
In the second study, treatment with Abasaglar or Lantus was compared in 759 patients with type 2 diabetes, as an addition to diabetes medicines taken by mouth.
V drugi študiji so primerjali zdravilo Abasaglar in zdravilo Lantus, ki so ju dodajali zdravilom za zdravljenje sladkorne bolezni, ki se jemljejo skozi usta, pri 759 bolnikih s sladkorno boleznijo tipa 2.
In the second trial, children aged from 2 to 15 years with moderate to severe atopic dermatitis received twice daily treatment for three weeks of 0.03% tacrolimus ointment, 0.1% tacrolimus ointment or 1% hydrocortisone acetate ointment.
V drugi raziskavi so se otroci stari od 2 do 15 let, z zmernim do hudim atopičnim dermatitisom tri tedne dvakrat na dan zdravili z 0,03% mazilom s takrolimusom, 0,1% mazilom s takrolimusom ali 1% mazilom s hidrokortizonacetatom.
In the second trial, conducted in Peru and enrolling military recruits, the short-term protective efficacy against cholera after 2 vaccine doses was 85% (95%CI: 36, 97, per-protocol analysis).
V drugem preskušanju, ki so ga opravili pri vojaških nabornikih v Peruju, je bila kratkoročna učinkovitost zaščite proti koleri po dveh odmerkih cepiva 85-odstotna (interval zaupanja 95 %: 36, 97, analiza po protokolih).
In the second trial, no delay in the time to disability progression was seen.
V drugi študiji niso opazili odloga do napredovanja invalidnosti.
In the second week, a patient’s assigned dose could be increased to 0.30 mg/kg if the patient had 2 or fewer rescue-free laxations up to day 8.
V drugem tednu se je lahko bolniku dodeljeni odmerek zvečal na 0,30 mg/kg, če je bolnik imel do 8. dneva največ 2 odvajanji brez rešilnega odvajala.
In the second year of life, Nimenrix can also be given at the same time as combined diphtheria - tetanus - acellular pertussis vaccines, including combination diphtheria - tetanus - acellular pertussis vaccines with hepatitis B, inactivated polio or Haemophilus influenzae type b, such as DTaP-HBV- IPV/Hib vaccine and 13-valent pneumococcal conjugate vaccine.
V drugem letu življenja se cepivo Nimenrix lahko uporabi sočasno s kombiniranimi cepivi proti davici-tetanusu-oslovskemu kašlju (brezcelično), vključno s kombinacijo cepiv proti davici-tetanusu- oslovskemu kašlju (brezcelično) s cepivom proti hepatitisu B, otroški paralizi (inaktivirano) ali Haemophilusu influenzae tipa b, npr. cepivom DTaP-HBV-IPV/Hib in 13-valentnim pnevmokoknim konjugiranim cepivom.
In the second year of the studies, efficacy was generally maintained through the last assessment at week 96, and 2-4% of patients required all injections on a monthly basis, and a third of patients required at least one injection with a treatment interval of only one month.
V drugem letu študij se je učinkovitost v splošnem ohranila do zadnjega ocenjevanja v 96. tednu; pri 2 – 4 % bolnikov so bile potrebne vse injekcije v intervalu enega meseca; pri tretjini bolnikov pa je bila po enem mesecu potrebna vsaj ena injekcija.
In the second year of the studies, patients continued to receive the initially randomised dosage but on a modified dosing schedule guided by assessment of visual and anatomic outcomes with a protocol- defined maximum dosing interval of 12 weeks.
V drugem letu študij so bolniki še naprej prejemali odmerke v jakostih, v katere so bili randomizirani na začetku, vendar s spremenjenim režimom odmerjanja, glede na oceno ostrine vida in anatomski izgled rumene pege, z največjim intervalom odmerjanja 12 tednov, kar je bilo opredeljeno v protokolu.
In the second year of the study women in the original Preotact group were randomly assigned to receive either alendronate or matching placebo, and women in the other two groups received alendronate.
V drugem letu študije so ženske, ki so prvotno prejemale zdravilo Preotact, naključno razporedili v skupini, ki sta prejemali bodisi alendronat bodisi placebo, ženske iz drugih dveh skupin pa so prejemale alendronat.
In the second year of treatment, 15 out of 17 patients had further improved weight-for-age percentiles (with individual patient treatment durations ranging from 78 to 142 weeks; mean follow-up period of weeks), 10 out of 16 patients had further improved length-for-age percentiles (with individual patient treatment durations ranging from 90 to 130 weeks; mean follow-up period of 113 weeks) and 11 out of 15 patients had further improved head circumference-for-age percentiles (with individual patient treatment durations ranging from 90 to 130 weeks; mean follow-up period of 110 weeks).
V drugem letu zdravljenja je 15 izmed 17 bolnikov še nadalje izboljšalo odstotek telesne mase glede na starost (s trajanjem zdravljenja pri posameznih bolnikih v razponu od 78 do 142 tednov; povprečno obdobje sledenja 111 tednov), 10 izmed 16 bolnikov je še nadalje izboljšalo odstotek višine glede na starost (s trajanjem zdravljenja pri posameznih bolnikih v razponu od 90 do 130 tednov; povprečno obdobje sledenja 113 tednov) ter 11 izmed 15 bolnikov je še nadalje izboljšalo odstotek obsega glave glede na starost (s trajanjem zdravljenja pri posameznih bolnikih v razponu od 90 do 130 tednov; povprečno obdobje sledenje 110 tednov).
In the setting of central nervous system (CNS) inflammation in MS, it is the interaction of α4β1 with VCAM-1, CS-1 and osteopontin that mediates the firm adhesion and transmigration of leukocytes into the brain parenchyma and may perpetuate the inflammatory cascade in CNS tissue.
V okviru vnetja osrednjega živčnega sistema pri MS je interakcija α4β1 z VCAM-1, CS-1 in osteopontinom posrednik čvrste adhezije in transmigracije levkocitov v možganski parenhim in lahko ohranja vnetno kaskado v tkivu osrednjega živčnega sistema.
In the setting of hyponatraemia, the treatment duration is determined by the underlying disease and its treatment.
Pri hiponatremiji se trajanje zdravljenja ugotavlja glede na osnovno bolezen in njeno zdravljenje.
In the short-term clinical studies of brivaracetam in epilepsy patients, there were no cases of completed suicide and suicide attempt, however both have been reported in open-label extension studies(see section 4.4).
Pri kratkotrajnih kliničnih študijah brivaracetama pri bolnikih z epilepsijo niso zabeležili primerov izvedenih samomorov ali poskusov samomora, vendar so o obojem poročali pri podaljšanih odprtih študijah (glejte poglavje 4.4).
In the short-term studies, Thymanax was seen to be more effective than placebo in the two studies where no active comparator was used.
V kratkotrajnih študijah se je zdravilo Thymanax izkazalo za učinkovitejše od placeba v dveh študijah, v katerih niso uporabili aktivnega primerjalnega zdravila.
In the short-term studies, Valdoxan was seen to be more effective than placebo in the two studies where no active comparator was used.
V kratkotrajnih študijah se je zdravilo Valdoxan izkazalo za učinkovitejše od placeba v dveh študijah, v katerih niso uporabili aktivnega primerjalnega zdravila.
In the short-term, placebo-controlled, fixed-dose adolescent study, a higher percentage of INVEGA-treated subjects (6-19% depending on dose) had an increase in body weight of ≥7% compared to placebo-treated subjects (2%).
V kratkotrajni, s placebom nadzorovani študiji z določenim odmerkom pri mladostnikih, je imel večji odstotek bolnikov, zdravljenih z zdravilom INVEGA (6-19%, odvisno od odmerka) za ≥7% povečano telesno maso v primerjavi z bolniki, ki so prejemali placebo (2%).
In the shorter (10 week) placebo controlled induction trial, GEMINI III, the types of adverse reactions reported were similar but occurred at lower frequency than the longer 52 week trials.
V krajšem (10-tedenskem), s placebom nadzorovanem indukcijskem preskušanju GEMINI III, so poročali o podobni vrsti neželenih učinkov, vendar pa je bila njihova pogostnost manjša, kot pri daljših, 52-tedenskih preskušanjih.
In the SINGLE study a mean change from baseline of 12.6 mol/L was observed after 96 weeks of treatment.
V študiji SINGLE je bil povprečni odklon od izhodiščne vrednosti 12,6 mol/L zabeležen po 96 tednih zdravljenja.
In the single-arm, open label trial in SAA, three (7%) patients were diagnosed with MDS following treatment with eltrombopag, in the two ongoing studies (ELT116826 and ELT116643), 1/28 (4%) and 1/62 (2%) subject has been diagnosed with MDS or AML in each study.
V odprti študiji z eno samo skupino bolnikov s hudo aplastično anemijo so po zdravljenju z eltrombopagom odkrili mielodisplastični sindrom (MDS) pri treh bolnikih (7 %), v dveh študijah, ki še potekata (študijah ELT116826 in ELT116643), pa so odkrili mielodisplastični sindrom ali akutno mieloično levkemijo pri 1/28 (4 %) oziroma 1/62 (2 %) preiskovancev.
In the single-arm, open-label trial in SAA, patients had bone marrow aspirates evaluated for cytogenetic abnormalities.
V odprti študiji z eno samo skupino bolnikov s hudo aplastično anemijo so pri bolnikih ocenjevali citogenetske nepravilnosti z aspiracijo kostnega mozga.
In the SIRTURO group, all of the five deaths due to tuberculosis occurred in patients whose sputum culture status at last visit was ‘not converted’.
V skupini, ki je prejemala zdravilo SIRTURO je bilo pet smrti posledica tuberkuloze pri bolnikih, katerih kulture sputuma pri zadnjem obisku niso kazale konverzije (odsotnosti povzročitelja v kužnini).
In the sixth study, Remicade alone and in combination with azathioprine was more effective than azathioprine alone; in ulcerative colitis, ankylosing spondylitis and psoriatic arthritis, more adult patients receiving Remicade had a reduction in symptoms than those receiving placebo.
V šesti študiji je bilo zdravilo Remicade kot samostojno zdravilo in v kombinaciji z azatioprinom učinkovitejše od samostojnega zdravljenja z azatioprinom; pri ulceroznem kolitisu, ankilozirajočem spondilitisu in psoriatičnem artritisu je bilo zmanjšanje simptomov opaziti pri več bolnikih, ki so prejemali zdravilo Remicade, kot pri tistih, ki so prejemali placebo.
In the small sample size for genotypic analysis, there was a trend toward a higher rate of NRTI-associated mutations in the once daily versus the twice daily abacavir regimens.
Pri genotipski analizi je bilo na majhnem vzorcu ugotovljeno, da je tendenca pojava mutacij, povezanih z NRTI večja pri režimu odmerjanju abakavirja enkrat dnevno kot pa pri režimu odmerjanja dvakrat dnevno.
In the small sample size for genotypic analysis, there was a trend toward a higher rate of NRTI-associated mutations in the once daily versus the twice daily abacavir regimens.
Pri genotipski analizi je bilo na majhnem vzorcu ugotovljeno, da je tendenca pojava mutacij, povezanih z NRTI večja pri režimu odmerjanju abakavirja enkrat na dan kot pa pri režimu odmerjanja dvakrat na dan.
In the small subgroup of patients with deletion 17p, only a positive trend was observed compared to Clb (HR=0.42, p=0.0892); no benefit was observed compared to RClb.
V majhni podskupini bolnikov z delecijo 17p so opazili le pozitiven trend v primerjavi z Clb (razmerje ogroženosti = 0,42, p = 0,0892); v primerjavi s RClb pa koristi niso opazili.
In the solvent the ingredients are mannitol and water.
Sestavini vehikla sta manitol in voda.
In the solvent: benzyl alcohol and benzalkonium chloride as preservatives and water for injections.
V vehiklu: benzilalkohol in benzalkonijev klorid kot konzervansa v 10 ml vode za injekcije.
In the solvent: carmellose sodium, sodium chloride, polysorbate 20, sodium dihydrogen phosphate monohydrate, disodium phosphate heptahydrate and water for injection.
V vehiklu: natrijev karmelozat, natrijev klorid, polisorbat 20, natrijev dihidrogen fosfat monohidrat, natrijev hidrogen fosfat heptahidrat in voda za injekcije.
In the solvent: carmellose sodium, sodium chloride, polysorbate 20, sodium dihydrogen phosphate monohydrate, disodium phosphate heptahydrate, water for injection and sodium hydroxide (for pH adjustment).
V vehiklu: natrijev karmelozat, natrijev klorid, polisorbat 20, natrijev dihidrogen fosfat monohidrat, natrijev hidrogen fosfat heptahidrat, voda za injekcije in natrijev hidroksid (za prilagoditev pH).
In the solvent: sodium chloride and water for injections
V vehiklu: natrijev klorid in voda za injekcije.
In the STPS, there were 84 evaluable zoster cases [8.4/1000 person-years] in the ZOSTAVAX group and 95 evaluable cases [14.0/1000 person-years] in the placebo group.
V študiji STPS je bilo v skupini s cepivom ZOSTAVAX 84 primerov herpesa zostra, ki jih je bilo možno ovrednotiti [8,4/1.000 oseb-let], v skupini s placebom pa 95 takih primerov [14,0/1.000 oseb- let].
In the stratum with baseline calculated GFR above 40 mL/min, the mean and median urinary protein to creatinine ratios were significantly higher in the Rapamune conversion group as compared to those of the calcineurin inhibitors continuation group at 24 months (see section 4.4).
V skupini z izhodiščno izračunano GFR nad 40 ml/min sta bila po 24 mesecih kvocienta povprečnih in medianih vrednosti beljakovin v urinu v primerjavi z vrednostmi kreatinina signifikantno večja v skupini po prehodu na zdravilo Rapamune kot v skupini, ki je nadaljevala z zaviralci kalcinevrina (glejte poglavje 4.4).
In the studies carried out during the development of Luveris, the combination of follitropin alfa and lutropin alfa at the same doses as in Pergoveris produced active follicles.
V študijah, izvedenih med razvojem zdravila Luveris, je kombinacija folitropina alfa in lutropina alfa v enakih odmerkih kot v zdravilu Pergoveris omogočila tvorjenje aktivnih foliklov.
In the studies comparing the two strengths of insulin glargine, Toujeo 300 units/ml strength was comparable to insulin glargine (100 units/ml) at controlling sugar levels.
V študijah, v katerih so primerjali obe jakosti insulina glargina, je bilo zdravilo Toujeo v jakosti 300 enot/ml pri uravnavanju ravni sladkorja v krvi primerljivo z insulinom glarginom 100 enot/ml.
In the studies in adults with schizoaffective disorder, Invega was more effective than placebo.
V študijah pri odraslih s shizoafektivno motnjo je bilo zdravilo Invega učinkovitejše od placeba.
In the studies in first line and previously treated patients no substantial differences in safety and efficacy related to age were observed; however the sizes of the databases are limited.
V študijah, ki so vključevale predhodno nezdravljene bolnike (zdravljenje prvega izbora) in pri že predhodno zdravljenih bolnikih ni mogoče opaziti znatnih razlik v varnosti ali učinkovitosti, povezanih s starostjo; vendar pa so podatki omejeni.
In the studies in newly diagnosed ovarian, fallopian tube and peritoneal cancer, average progression- free survival was 19.3 months with Avastin versus 16.9 months with carboplatin and paclitaxel alone in one study, and 14.7 months versus 10.6 months in the second study.
V študijah na novo diagnosticiranega raka jajčnikov, jajcevodov in potrebušnice je v eni študiji povprečni čas preživetja brez napredovanja bolezni znašal 19,3 meseca pri bolnikih, ki so prejemali zdravilo Avastin, v primerjavi s 16,9 meseca pri tistih, ki so prejemali samo karboplatin in paklitaksel, v drugi študiji pa 14,7 meseca v primerjavi z 10,6 meseca.
In the studies in patients with earlier stages of breast cancer who were to undergo surgery, Perjeta was shown to improve response to treatment.
Študije so pokazale, da je zdravilo izboljšalo odziv na zdravljenje pri bolnikih z zgodnjim stadijem raka dojk, in pri katerih naj bi bil opravljen kirurški poseg.
In the studies in the treatment and prevention of swine dysentery, Econor in feed at a dose of 3-4 mg valnemulin/kg bodyweight/day (i.e.
V študijah zdravljenja in preprečevanja prašičje griže so to bolezen uspešno zdravili z dajanjem zdravila Econor v krmo v odmerku 3–4 mg valnemulina/kg telesne mase/dan (tj.
In the studies in the treatment and prevention of swine enzootic pneumonia, Econor in feed at a dose of 10-12 mg valnemulin/kg bodyweight (i.e.
V študijah zdravljenja in preprečevanja enozootske pljučnice pri prašičih so z zdravilom Econor v krmi v odmerku 10–12 mg valnemulina/kg telesne mase (tj.
In the studies looking at the dispersible tablets, the levels of bosentan were lower than expected from the results of other studies, and could not be increased by using a higher dosing of Tracleer.
V študijah z disperzibilnimi tabletami so bile ravni bosentana nižje od pričakovanih glede na rezultate drugih študij, in se jih tudi z višjimi odmerki zdravila Tracleer ni dalo povečati.
In the studies looking at treatment of VTE and PE, blood clots or blood-clot related death occurred in 2.7% (68 out of 2553) of patients treated with Pradaxa, compared with 2.4% (62 out of 2554) of patients treated with warfarin.
V študijah zdravljenja globoke venske tromboze in pljučne embolije, so se krvni strdki oziroma smrt bolnika zaradi krvnih strdkov pojavili pri 2,7 % (68 od 2 553) bolnikov, zdravljenih z zdravilom Pradaxa, v primerjavi z 2,4 % (62 od 2 554) bolnikov, zdravljenih z varfarinom.